Cerebrospinal fluid alzheimer biomarkers ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Cerebrospinal fluid alzheimer biomarkers can be useful for discriminating dementia with lewy bodies from alzheimer's disease at the prodromal stage
Auteur(s) :
Bousiges, Olivier [Auteur]
Bombois, Stephanie [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Schraen, Susanna [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Wallon, David [Auteur]
Quillard-Muraine, Muriel [Auteur]
Gabelle, Audrey [Auteur]
Lehmann, Sylvain [Auteur]
Paquet, Claire [Auteur]
Bouaziz-Amar, Elodie [Auteur]
Magnin, Eloi [Auteur]
Miguet-Alfonsi, Carole [Auteur]
Delbeuck, Xavier [Auteur]
Lavaux, Thomas [Auteur]
Anthony, Pierre [Auteur]
Philippi, Nathalie [Auteur]
Blanc, Frederic [Auteur]
Bombois, Stephanie [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Schraen, Susanna [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Wallon, David [Auteur]
Quillard-Muraine, Muriel [Auteur]
Gabelle, Audrey [Auteur]
Lehmann, Sylvain [Auteur]
Paquet, Claire [Auteur]
Bouaziz-Amar, Elodie [Auteur]
Magnin, Eloi [Auteur]
Miguet-Alfonsi, Carole [Auteur]
Delbeuck, Xavier [Auteur]
Lavaux, Thomas [Auteur]
Anthony, Pierre [Auteur]
Philippi, Nathalie [Auteur]
Blanc, Frederic [Auteur]
Titre de la revue :
Journal of neurology, neurosurgery, and psychiatry
Nom court de la revue :
J. Neurol. Neurosurg. Psychiatry
Date de publication :
2018-01-10
ISSN :
1468-330X
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau181
A total of 1221 CSF ...
Lire la suite >Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau181 A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively. Samples were obtained from patients with prodromal DLB (pro-DLB; n=57), DLB dementia (DLB-d; n=154), prodromal AD (pro-AD; n=132) and AD dementia (n=783), and control subjects (CS; n=95). These centres use the same diagnostic procedure and criteria to evaluate the patients. In patients with pro-DLB, CSF Aβ42 levels appeared much less disrupted than in patients at the demented stage (DLB-d) (P<0.05 CS>pro-DLB; P<0.001 CS>DLB-d). On average, Aβ40 levels in patients with DLB (pro-DLB and DLB-d) were much below those in patients with pro-AD (P<0.001 DLB groups<pro-AD). The Aβ42/Aβ40 ratio in patients with pro-DLB remained close to that of CS. t-Tau and phospho-Tau181 Reduced levels of CSF Aβ42 were found in patients with DLB but rather at a later stage, reaching those of patients with AD, in whom Aβ42 levels were decreased even at the prodromal stage. At the prodromal stage of DLB, the majority of patients presented a normal CSF profile. CSF t-Tau and phospho-Tau181Lire moins >
Lire la suite >Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau181 A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively. Samples were obtained from patients with prodromal DLB (pro-DLB; n=57), DLB dementia (DLB-d; n=154), prodromal AD (pro-AD; n=132) and AD dementia (n=783), and control subjects (CS; n=95). These centres use the same diagnostic procedure and criteria to evaluate the patients. In patients with pro-DLB, CSF Aβ42 levels appeared much less disrupted than in patients at the demented stage (DLB-d) (P<0.05 CS>pro-DLB; P<0.001 CS>DLB-d). On average, Aβ40 levels in patients with DLB (pro-DLB and DLB-d) were much below those in patients with pro-AD (P<0.001 DLB groups<pro-AD). The Aβ42/Aβ40 ratio in patients with pro-DLB remained close to that of CS. t-Tau and phospho-Tau181 Reduced levels of CSF Aβ42 were found in patients with DLB but rather at a later stage, reaching those of patients with AD, in whom Aβ42 levels were decreased even at the prodromal stage. At the prodromal stage of DLB, the majority of patients presented a normal CSF profile. CSF t-Tau and phospho-Tau181Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Équipe(s) de recherche :
Alzheimer et Tauopathies
Troubles cognitifs dégénératifs et vasculaires
Troubles cognitifs dégénératifs et vasculaires
Date de dépôt :
2019-11-27T14:28:54Z